[Drug eluting stents as the new direction of cardiovascular prothesis research].
In 1986 Puel and Sigwart placed first coronary stent in human body and therefore have opened a new chapter in percutaneous coronary intervention (PCI). In the beginning, stenting was performed during balloon angioplasty complications. However, 10 years after first implantation, PCI has become a widely used independent technique of widening the lumen of coronary arteries and fighting against coronary arteriosclerosis. Currently this method is rapidly developing, moreover, research centres have proposed its several improvements. A significant modification of the technique was the introduction of Drug Eluting Stents (DES) coated with active substances what enabled to prevent. In 2002 first stent coated with sirolimus was marketed in Europe and a year later was approved by FDA (Food and Drug Administration). Since then DES has lead the way of coronary artery stenting.
Guzik
Łukasz
Ł
Katedra i Zakład Chemii Nieorganicznej, Wydzial Farmaceutyczny, Gdański Uniwersytet Medyczny. lguzik@gumed.edu.pl
Nasternak
Magdalena
M
Maciejewski
Michał
M
D020341:Absorbable Implants; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000628:therapy*; D020099:Coated Materials, Biocompatible; D023903:Coronary Restenosis / Q000209:etiology; D054855:Drug-Eluting Stents; D006801:Humans; D011108:Polymers; D013927:Thrombosis / Q000209:etiology
D020099:Coated Materials, Biocompatible; D011108:Polymers